One-Year Outcome of Glycoprotein IIb/IIIa Inhibitor Therapy in Patients with Myocardial Infarction-Related Cardiogenic Shock.
Krzysztof MyrdaMariusz GąsiorDariusz DudekBartłomiej NawrotekJacek NiedzielaWojciech WojakowskiMarek GierlotkaMarek GrygierJanina StępińskaAdam WitkowskiMaciej LesiakJacek LegutkoPublished in: Journal of clinical medicine (2021)
The addition of GPIs to the standard pharmacotherapy combined with PCI in patients with MI and CS on admission reduced the risk of death in the 12-month follow-up period without increasing in-hospital adverse event rates.
Keyphrases
- adverse drug
- emergency department
- coronary artery disease
- heart failure
- percutaneous coronary intervention
- acute myocardial infarction
- acute coronary syndrome
- healthcare
- antiplatelet therapy
- smoking cessation
- atrial fibrillation
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- coronary artery bypass grafting
- stem cells
- bone marrow
- drug induced